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Accepted 27 December 2011AbstractObjective: SertolieLeydig cell tumor (SLCT) accounts for <0.5% of all ovarian tumors, which is unusual in postmenopausal women. Post-
menopausal women with SLCT usually become virilized. We report a postmenopausal woman with SLCT presenting with hyperestrogenism.
Case Report: We report a rare case of SLCT in a postmenopausal woman aged 61 years, who presented with postmenopausal bleeding,
endometrial hyperplasia and mucous polyp, elevated estradiol, and decreased follicle-stimulating hormone (FSH) and luteinizing hormone (LH)
values, all suggesting hyperestrogenism. Transvaginal ultrasound revealed several small cyst locules, detected inside the right ovary, with
a maximum diameter of 7 mm. The diagnosis was delayed because of the atypical clinical manifestation and negative serum tumor markers. The
frozen section investigation revealed SLCT intraoperatively, which was confirmed by histopathological and immunocytochemical examination.
The tumor was positive for inhibin-alpha, pancytokeratin, and p53 and in isolated tumor cells, positive for Ki-67.
Conclusion: This case of SLCT suggests the existence of a new specific type of endocrine complex disease.
Copyright  2012, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Sertoli-Leydig cell tumor (SLCT) belongs to the group of
sex cord-stromal tumors (SCST) of the ovary, which accounts
for <0.5% of all ovarian tumors [1]. Approximately three-
quarters of these tumors occur at the age of 20e30 years
and <10% occur either prior to menarche or after menopause
[2], although the youngest case was reported to be 12 months
old [3]. The clinical characteristics of SLCT are reported to be
associated to the degree of histological differentiation [4].
SLCT is usually associated with virilization [5]; association
with hyperestrogenism is very rare in postmenopausal women.
We present a case of SLCT with symptoms associated with* Corresponding author. Changle Road, 536, Shanghai 200040, China.
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http://dx.doi.org/10.1016/j.tjog.2012.09.019increased estrogen levels, instead of virilization, in a post-
menopausal woman. We believe that our case is a useful
addition to the literature.
Case report
A 61-year-old woman, G2P1, had her last menstrual period
at the age of 55, but presented with regular postmenopausal
bleeding 1 year ago. She experienced each postmenopausal
bleeding for approximately 1 week every month, which was
similar to normal menstruation. The patient underwent hys-
teroscopy for postmenopausal bleeding; an endometrial polyp
was removed and histological examination revealed the simple
endometrial hyperplasia. The patient was administered oral
norethisterone and monitored by pelvic ultrasound monthly,
which showed the development of a progressively thickened
endometrium and a slightly enlarged right ovary measuringcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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bleeding became irregular and the amount of bleeding was
reduced.
The patient was admitted to our hospital and transvaginal
ultrasound revealed several small cyst locules detected inside
the enlarged right ovary, with a maximum diameter of 7 mm.
Laboratory examination revealed an elevated estradiol level of
64.90 pg/mL, a suppressed follicle-stimulating hormone
(FSH) level of 5.25 IU/L and a luteinizing hormone (LH) level
of 1.87 IU/L. The hormonal profile of the case also included
normal testosterone, thyrotropin and progesterone in serum.
Tumor markers, including CA125, CA199, alpha-fetoprotein
(AFP) and carcinoembryonic antigen (CEA), were all within
normal limits. A chest X-ray showed no evidence of pleural
effusion or lung metastasis. An ovarian malignancy was not
suspected, because of the atypical ovarian mass and negative
tumor markers in serum. Some gynecologists suggested
conservative observation, while others advocated oophorec-
tomy. Informed consent was obtained from the patient.
A diagnostic laparoscopy was initially performed, with theFig. 1. Hematoxylin and eosin stains for the SertolieLeydig cell tumor
(200). (A) Photomicrograph of the frozen section; (B) photomicrograph of
the paraffin section. Clusters of Leydig cells were large and polygonal with
eosinophilic cytoplasm, as indicated by black arrows, which were next to the
tubules of tumoral Sertoli cells, as indicated by white arrows.finding of a 3  2  2 cm right ovarian mass and several small
cysts inside the ovary. Hysteroscopy was also performed
spontaneously, with the finding of a 0.5  0.6 cm endometrial
polyp at five o’clock in the uterine cavity. Right oophorec-
tomy, combined with endometrial polypectomy was per-
formed. Frozen section investigation revealed a SLCT of the
right ovary (Fig. 1A) and a laparotomy was performed with
total hysterectomy, left oophorectomy, omentectomy, appen-
dectomy, resection of infundibulopelvic ligament, peritoneal
biopsies, and pelvic and para-aortic lymph nodes biopsies.
Pathological analysis confirmed a SLCT of the right ovary,
with a high degree of differentiation (Fig. 1B). No areas of
malignant transformation were identified on multiple sections
of the surgical specimen. Immunohistochemical analysis
showed a strong positive stain for inhibin-alpha, pan-cyto-
keratin (pan-CK) (Fig. 2A and B), and positive results for P53
(Fig. 3A). Five percent of tumor cells were positive for Ki-67
staining (Fig. 3B), whereas progesterone receptor (PR),
estrogen receptor (ER), epithelial membrane antigen (EMA)
and CD99 were negative (Fig. 3CeF).Fig. 2. Immunohistochemical analysis for the SertolieLeydig cell tumor
(400). (A) Strong inhibin-alpha immunoreactivity in Sertoli and Leydig
cells; (B) strong positive stain of pan-cytokeratin in Sertoli cells.
Fig. 3. Immunohistochemical analysis for the SertolieLeydig cell tumor (400). (A) positive stain of P53 in Sertoli cells; (B) positive in 5% of tumor cells with
Ki-67 stain; (C) negative for stain of progesterone receptors; (D) negative for stain of estrogen receptors; (E) negative for stain of epithelial membrane antigen; (F)
negative for stain of CD99.
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ized, and there was no sign of recurrence at her first follow-up
visit 3 months postoperatively.
Discussion
SLCT belongs to the group of SCST of the ovary, which is
usually unilateral [1]. Young women with SLCT are usually
characterized by virilization [6]. Occurrence in post-
menopausal women is very rare [5]. Endocrine symptoms are
absent from approximately half of patients and more than
one-third of these patients develop signs of virilization, such
as increasing facial hair growth, deepening of the voice,
a dull pain in the lower part of the abdomen, and enlarge-
ment of the clitoris, by hormonal hyperproduction of
testosterone, but they rarely present manifestations of
hyperestrogenism.
In our case, the main clinical features were postmenopausal
bleeding, endometrial hyperplasia and mucous polyp,indicating hyperestrogenism in the patient. Hormone assays
were dominated by high serum estradiol values and suppressed
FSH and LH, which were consistent with the hyperestrogenic
symptoms. The high production of estrogens in our patient
with SLCT, was consistent with the observation of excessive
secretion of estrogens in a nonhuman primate animal model,
which might have originated in the hypertrophic thecal tissue
rather than in the tumor [7].
We reviewed the literature on SLCT in postmenopausal
women and found that there was only one out of 10 cases
(10%) who presented with hyperestrogenism (Table 1). The
patient, reported by Dhont et al in 1986, experienced post-
menopausal bleeding, and endometrial mucous polyp and
hyperplasia [5]. In another report, Young et al described that
5.6% patients (2/38) presented postmenopausal bleeding in
patients with SLCT containing heterologous elements in the
form of gastrointestinal-type epithelium [8], whereas Demidov
et al reported that 20% (3/15) of SLCT patients had post-
menopausal bleeding. However, a hormone profile was not
Table 1
Review of the literature on SertolieLeydig cell tumor in postmenopausal women.
Authors Year Age (y) Signs of hyperandrogenism Signs of hyperestrogenism
Clinton et al [16] 1981 65 No No
Dhont et al [5] 1986 73 No Yes
Mango et al [17] 1988 59 Yes No
Hansen and Sorensen [18] 1993 65 Yes No
Cohen et al [19] 1993 60 Yes No
Gheorghisan-Galateanu et al [9] 2003 69 Yes No
Tampakoudis et al [20] 2004 71 No No
Dahlgren et al [21] 2005 64 Yes No
Caringella et al [22] 2006 65 Yes No
Herrera et al [23] 2009 56 Yes No
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were caused by elevated estradiol levels.
Immunohistochemistry is useful for the differential diag-
nosis of SLCT with other ovarian tumors [9]. In our case,
tumor cells were positive for pan-CK, inhibin-a, and P53
protein, while Ki-67 was positive in 5% of tumor cells.
Immunoassaying for PR, ER, EMA and CD 99 resulted in
a negative reactivity in the tumor cells.
Increased production of inhibin was reported in SLCT [10],
which was consistent with the immunohistochemical findings
in our case. Furthermore, the association of positive staining
for inhibin-a and negative staining for EMA supported the
diagnosis of a SCST [11]. Negative results of ER and PR were
reported to be a useful addition to traditional immunohisto-
chemical markers, such as EMA, inhibin, CD99 and pan-CK,
to distinguish Sertoli cell tumors from endometrioid tumors
[12]. PR in our case was negative, although it was reported to
be positive in 13% of Sertoli cell tumors [12]. In the present
study, the expression of Ki-67 was positive in 5% of Leydig
cells, while another study reported <2% [13]. The positive
reaction for p53 antibodies observed in this study was
consistent with findings in a 17- and a 33-year-old female in
previous literature, which could probably be associated with
the degree of gonadal development [14].
The tumor can be undetectable by pelvic ultrasound when it
is small in dimensions, although ultrasound examination of the
ovaries is recommended as the first choice of diagnostic
procedure. SLCTs were either moderately or abundantly vas-
cularized purely solid tumors or multilocular solid tumors with
areas of innumerable closely packed small cyst locules mixed
with solid areas [15]. The tumor in our patient was relatively
small, but it presented several small cyst locules detected inside
the right ovary, with a maximum diameter of 7 mm. The small
dimension of the tumor was reported to be correlated with the
good differentiation, while poorly differentiated tumors can
reach up to 10e15 cm [4]. In this study, the high differentiation
of SLCT could also be associated with its limited dimensions.
When SLCT patients had both a small ovarian mass and
negative tumor markers in serum, as with the case in our study,
it was possibly misdiagnosed with non-malignant disease.
Conservative observation should be cautiously adapted,
because it might delay the necessary surgical intervention.
Furthermore, hyperestrogenism could be associated withSLCT in a small portion of postmenopausal patients, although
most patients have no endocrine symptoms or virilization.
In conclusion, the present study shows a postmenopausal
case of SLCT, with well-differentiated pathology. The pre-
senting manifestations of postmenopausal bleeding associated
with hyperestrogenism in our case, might suggest the exis-
tence of a new specific type of endocrine complex disease.References
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